

Table 1: Baseline characteristics in participants without type 2 diabetes at baseline

Characteristic	Dapagliflozin 10 mg (n=1,995)	Placebo (n=2,008)	Total (n=4,003)
Study n (%)			
DAPA-HF	1,298 (65.1)	1,307 (65.1)	2,605 (65.1)
DAPA-CKD	697 (34.9)	701 (34.9)	1,398 (34.9)
Age, years, mean (SD)	62.8 (13.5)	62.7 (13.6)	62.8 (13.6)
Age category, years, n (%)			
≤65	1,029 (51.6)	1,052 (52.4)	2,081 (52.0)
>65	966 (48.4)	956 (47.6)	1,922 (48.0)
Sex, n (%)			
Male	1,456 (73.0)	1,455 (72.5)	2,911 (72.7)
Female	539 (27.0)	553 (27.5)	1,092 (27.3)
Race*, n (%)			
White	1,291 (64.7)	1,302 (64.8)	2,593 (64.8)
Black or African American	78 (3.9)	74 (3.7)	152 (3.8)
Asian	579 (29.0)	581 (28.9)	1,160 (29.0)
Other	47 (2.4)	51 (2.5)	98 (2.4)
Region, n (%)			
Asia	560 (28.1)	562 (28.0)	1,122 (28.0)
Europe	844 (42.3)	821 (40.9)	1665 (41.6)
North America	267 (13.4)	265 (13.2)	532 (13.3)
Latin America	324 (16.2)	360 (17.9)	684 (17.1)
Glycaemia subgroup, n (%)			
Normoglycaemia	806 (40.4)	789 (39.3)	1595 (39.8)
Prediabetes	1189 (59.6)	1219 (60.7)	2408 (60.2)
HbA1c, %, mean (SD)	5.7 (0.4)	5.7 (0.4)	5.7 (0.4)
eGFR, mL/min/1.73 m², mean (SD)	58.7 (21.1)	58.7 (21.0)	58.7 (21.0)
eGFR category, mL/min/1.73 m², n (%)			
<30	107 (5.4)	124 (6.2)	231 (5.8)
30 to <45	499 (25.0)	465 (23.2)	964 (24.1)
45 to <60	516 (25.9)	525 (26.1)	1041 (26.0)
≥60	872 (43.7)	893 (44.5)	1765 (44.1)
Systolic blood pressure, mmHg, mean (SD)	125.0 (17.2)	124.6 (17.3)	124.8 (17.2)
Systolic blood pressure category, mmHg, n (%)			
<130	1263 (63.3)	1283 (63.9)	2546 (63.6)
≥130	732 (36.7)	725 (36.1)	1457 (36.4)
Diastolic blood pressure, mmHg, mean (SD)	75.6 (11.1)	75.4 (11.0)	75.5 (11.1)
Body Mass Index, kg/m², mean (SD)	27.4 (5.7)	27.5 (5.7)	27.5 (5.7)
Body Mass Index category, kg/m², n (%)			
<25	632 (31.7)	632 (31.5)	1264 (31.6)
25 to <30	765 (38.3)	756 (37.6)	1521 (38.0)
≥30	595 (29.8)	620 (30.9)	1215 (30.4)
Heart failure at baseline, n (%)	1356 (68.0)	1356 (67.5)	2712 (67.7)

Coronary heart disease at baseline, n (%)	804 (40·3)	826 (41·1)	1630 (40·7)
Cardiovascular disease at baseline, n (%)	1471 (73·7)	1463 (72·9)	2934 (73·3)
Current smoker, n (%)	277 (13·9)	317 (15·8)	594 (14·8)
Baseline medication, n (%)			
Diuretics	1154 (57·8)	1193 (59·4)	2347 (58·6)
Loop diuretics	1098 (55·0)	1130 (56·3)	2228 (55·7)
Thiazides	213 (10·7)	220 (11·0)	433 (10·8)
ACE inhibitor/ARB	1897 (95·1)	1907 (95·0)	3804 (95·0)
Statins	1143 (57·3)	1176 (58·6)	2319 (57·9)
Beta-blocker	1459 (73·1)	1445 (72·0)	2904 (72·5)
Mineralocorticoid receptor antagonists	940 (47·1)	959 (47·8)	1899 (47·4)

Pooled data from the DAPA-CKD and DAPA-HF trials

*Self-reported

ACE = angiotensin-converting enzyme. ARB = angiotensin receptor blocker. eGFR = estimated glomerular filtration rate.